We are live on
!
Find out more
3C
361 Capital Portfolio holdings
AUM
$213M
1-Year Est. Return
24.26%
This Fund
S&P 500
This Quarter
Est. Return
-20.52%
1 Year Est. Return
+24.26%
3 Year Est. Return
+117.64%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$220M
AUM Growth
-$141M
(-39%)
Cap. Flow
-$75.9M
Cap. Flow
% of AUM
-34.5%
Top 10 Holdings %
Top 10 Hldgs %
7.96%
Holding
421
New
120
Increased
25
Reduced
138
Closed
136
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Williams Companies
WMB
|
+$1.94M |
| 2 |
BERY
Berry Global Group, Inc.
BERY
|
+$1.81M |
| 3 |
TransUnion
TRU
|
+$1.79M |
| 4 |
RenaissanceRe
RNR
|
+$1.76M |
| 5 |
SBNY
Signature Bank
SBNY
|
+$1.71M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$2.21M |
| 2 |
PACCAR
PCAR
|
+$2.16M |
| 3 |
Spotify
SPOT
|
+$2.12M |
| 4 |
US Foods
USFD
|
+$2.06M |
| 5 |
ONE Gas
OGS
|
+$1.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.83% |
| 2 | Healthcare | 15.4% |
| 3 | Industrials | 12.81% |
| 4 | Financials | 12.39% |
| 5 | Real Estate | 6.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
GATX Corp
GATX
$6.6B
| $1.34M | 0.61% |
21,506
-3,156
| -13% | -$230K |
|
27
Leidos
LDOS
$14.9B
| $1.34M | 0.61% |
14,666
-3,221
| -18% | -$325K |
|
28
Huntington Ingalls Industries
HII
$11.8B
| $1.3M | 0.59% |
7,151
+5,139
| +255% | +$1.2M |
|
29
Zillow
Z
$7.7B
| $1.29M | 0.58% |
+35,694
| New | +$1.65M |
|
30
Keysight
KEYS
$52.2B
| $1.27M | 0.58% |
15,235
+3,802
| +33% | +$361K |
|
31
SS&C Technologies
SSNC
$18.8B
| $1.26M | 0.57% |
+28,823
| New | +$1.63M |
|
32
Fox Class A
FOXA
$24.2B
| $1.25M | 0.57% |
53,102
-5,388
| -9% | -$177K |
|
33
Lumentum
LITE
$50.7B
| $1.25M | 0.57% |
+17,004
| New | +$1.34M |
|
34
Schwab US Large- Cap ETF
SCHX
$71.3B
| $1.24M | 0.56% |
121,350
-27,534
| -18% | -$334K |
|
35
Teledyne Technologies
TDY
$30.1B
| $1.23M | 0.56% |
4,145
-561
| -12% | -$193K |
|
36
Jack Henry & Associates
JKHY
$11.2B
| $1.23M | 0.56% |
+7,924
| New | +$1.23M |
|
37
Regeneron Pharmaceuticals
REGN
$72.9B
| $1.2M | 0.54% |
2,455
+963
| +65% | +$397K |
|
38
Teradyne
TER
$50.2B
| $1.17M | 0.53% |
21,498
-4,155
| -16% | -$264K |
|
39
SolarEdge
SEDG
$2.44B
| $1.12M | 0.51% |
13,624
-1,624
| -11% | -$172K |
|
40
Merck
MRK
$326B
| $1.11M | 0.5% |
15,063
+2,582
| +21% | +$203K |
|
41
Markel Group
MKL
$25.5B
| $1.1M | 0.5% |
+1,186
| New | +$1.36M |
|
42
Schwab Short-Term US Treasury ETF
SCHO
$12.8B
| $1.09M | 0.5% |
42,338
+1,760
| +4% | +$44.8K |
|
|
SBNY
43
DELISTED
Signature Bank
SBNY
| $1.09M | 0.5% |
+13,582
| New | +$1.71M |
|
44
Emergent Biosolutions
EBS
$377M
| $1.07M | 0.49% |
18,555
-4,401
| -19% | -$254K |
|
45
Gen Digital
GEN
$16.6B
| $1.05M | 0.48% |
+55,916
| New | +$1.21M |
|
46
Kimberly-Clark
KMB
$37.5B
| $1.04M | 0.47% |
+8,118
| New | +$1.12M |
|
47
Schwab US Mid-Cap ETF
SCHM
$14.5B
| $1.03M | 0.47% |
73,371
-17,325
| -19% | -$317K |
|
48
Vertex Pharmaceuticals
VRTX
$124B
| $1.03M | 0.47% |
+4,315
| New | +$990K |
|
49
Arcosa
ACA
$7.13B
| $1.02M | 0.47% |
25,764
-6,110
| -19% | -$258K |
|
50
Southern Company
SO
$109B
| $1.01M | 0.46% |
18,705
-3,066
| -14% | -$194K |
|
Similar funds
SIA
PV
RCM
ALIA
TL
RI
SMFS
HF
361 Capital's Q1 2020 Portfolio in Review
As of Q1 2020, 361 Capital held 421 positions worth $220M, down 39% from $361M the previous quarter. Its ten largest holdings account for 8% of the portfolio.
361 Capital withdrew a net $75.9M in Q1 2020, closing 136 positions and reducing 138 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $2.21M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 13% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, 361 Capital opened a new position in Williams Companies worth $1.42M.
- 361 Capital's largest Q1 2020 buy was Williams Companies: 100,317 shares worth $1.42M.
- 361 Capital added most to Huntington Ingalls Industries in Q1 2020, an estimated $1.2M increase.
- 361 Capital's biggest Q1 2020 reduction was Zebra Technologies, cutting an estimated $1.52M.
- 361 Capital fully exited Jazz Pharmaceuticals in Q1 2020, selling an estimated $2.21M.
- 361 Capital's ten largest holdings make up 8% of its $220M portfolio in Q1 2020.
- 361 Capital opened 120 new positions and closed 136 in Q1 2020.
- 361 Capital's portfolio value fell 39% quarter-over-quarter to $220M.
Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.